Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$13.81 USD
-0.05 (-0.36%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $13.79 -0.02 (-0.14%) 4:28 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LQDA 13.81 -0.05(-0.36%)
Will LQDA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LQDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LQDA
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
LQDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Other News for LQDA
Buy Rating for Liquidia Technologies: Innovation and Market Potential Drive Strong Investment Case
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)
Buy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies’ Yutrepia
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder